Soft tissue sarcoma of the extremity: the decisions you may face
4 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Localised, resectable
Limb-sparing wide resection with preoperative (50 Gy) or postoperative (66 Gy) radiotherapy for high-grade or deep tumours over 5 cm; surgery alone for small superficial low-grade tumours.
Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.
- Preserves function without compromising survival
- Custom implants for pelvis and spine
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
- Conformal dose, fewer side effects
- Hypofractionation saves visits
Brachytherapy places a radioactive source directly inside or next to the tumour.
- Highest conformality
- Short treatment
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Implant infection and mechanical failure over decades
- Requires specialist sarcoma centres
- Low-dose bath to normal tissue
- Motion management
- Invasive
- Declining expertise in some regions
- Between Limb-salvage surgery and endoprosthetic reconstruction, IMRT / IGRT (modern external beam) and Brachytherapy, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (localised, resectable), which of the standard options do you recommend and why?Why: Guideline options include: Limb-sparing wide resection with preoperative (50 Gy) or postoperative (66 Gy) radiotherapy for high-grade or deep tumours over 5 cm; surgery alone for small superficial low-grade tumours.
Add these to your appointment list, or take the full question set for this cancer.
High-risk localised (large, deep, high grade)
Neoadjuvant anthracycline-ifosfamide (ISG-STS 1001) in fit patients; regional hyperthermia with chemotherapy or isolated limb perfusion for borderline resectable tumours.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
Hyperthermia heats tumours to 40-43 °C to make radiation and chemotherapy work better.
- Radiosensitiser without added toxicity
Isolating the blood supply of an arm or leg so that chemotherapy doses 15-20 times higher than the body could tolerate can be circulated through it, to save limbs with melanoma or sarcoma that would otherwise be amputated.
- Limb salvage in otherwise unresectable sarcoma
- High complete response in melanoma in-transit disease
- Minimal systemic toxicity when leak is controlled
- Tests IfosfamideHigh-risk localised soft-tissue sarcoma of extremities/trunk: neoadjuvant epirubicin-ifosfamide vs histotype-tailored chemotherapy
Standard arm DFS HR ~0.45 vs tailored; OS 89% vs 64% at 46 months.
Overall survival at 46 months (%): Epirubicin-ifosfamide 89 (n=142) vs Histotype-tailored 64 (n=145) · source
- Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
- Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.
- Equipment and expertise scarce
- Major operation; regional toxicity (Wieberdink grade)
- TNF-α not approved in the US
- Displaced in melanoma by systemic immunotherapy
- Between Doxorubicin, Ifosfamide, Hyperthermia and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in ISG-STS 1001, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (high-risk localised (large, deep, high grade)), which of the standard options do you recommend and why?Why: Guideline options include: Neoadjuvant anthracycline-ifosfamide (ISG-STS 1001) in fit patients; regional hyperthermia with chemotherapy or isolated limb perfusion for borderline resectable tumours.
- Am I a candidate for Doxorubicin, Ifosfamide, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of ISG-STS 1001 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Advanced, first line
Doxorubicin alone, or doxorubicin plus ifosfamide when shrinkage is needed (EORTC 62012); doxorubicin plus trabectedin for leiomyosarcoma (LMS-04); olaratumab withdrawn after ANNOUNCE.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.
A chemotherapy derived from a sea squirt, used with liposomal doxorubicin in relapsed ovarian cancer in Europe and for sarcomas.
- Tests Doxorubicin, IfosfamideAdvanced soft tissue sarcoma, first line: doxorubicin plus ifosfamide versus doxorubicin alone
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Median OS 14.3 vs 12.8 months (HR 0.83, not significant); median PFS 7.4 vs 4.6 months (HR 0.74).
Overall survival (median) (months): Doxorubicin + ifosfamide 14.3 vs Doxorubicin 12.8 · HR 0.83 · source - Tests Doxorubicin, TrabectedinMetastatic or unresectable leiomyosarcoma, first line: doxorubicin plus trabectedin (then trabectedin maintenance) versus doxorubicin
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Median PFS 12.2 vs 6.2 months (HR 0.41); overall survival also favoured the combination at later follow-up.
Progression-free survival (median) (months): Doxorubicin + trabectedin 12.2 vs Doxorubicin 6.2 · HR 0.41 · source - Tests DoxorubicinAdvanced soft-tissue sarcoma, first line: olaratumab + doxorubicin vs doxorubicin
OS HR 1.05 (negative); drug withdrawn.
Overall survival (median) (months): Olaratumab + doxorubicin 20.4 (n=258) vs Doxorubicin 19.7 (n=251) · HR 1.05 · source
- Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
- Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.
- Alcohol: avoid (hepatotoxicity). Dexamethasone 20 mg before each dose protects the liver.
- Reduce to 0.9 mg/m² in moderate impairment; avoid in severe.
- Between Doxorubicin, Ifosfamide and Trabectedin, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in EORTC 62012 and LMS-04, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (advanced, first line), which of the standard options do you recommend and why?Why: Guideline options include: Doxorubicin alone, or doxorubicin plus ifosfamide when shrinkage is needed (EORTC 62012); doxorubicin plus trabectedin for leiomyosarcoma (LMS-04); olaratumab withdrawn after ANNOUNCE.
- Am I a candidate for Doxorubicin, Ifosfamide, Trabectedin, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EORTC 62012 and LMS-04 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Later lines and oligometastatic
Gemcitabine-docetaxel, pazopanib, trabectedin, eribulin (liposarcoma); pulmonary metastasectomy or stereotactic radiotherapy for limited lung disease; histology-directed agents and trials.
A versatile chemotherapy used in pancreatic, bladder, lung, ovarian, breast and biliary cancers, in nasopharyngeal cancer, and as a bladder instillation.
The first chemotherapy to extend life in prostate cancer (2004), now part of triplet therapy at first metastatic diagnosis.
Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.
A chemotherapy derived from a sea squirt, used with liposomal doxorubicin in relapsed ovarian cancer in Europe and for sarcomas.
A sea-sponge-derived chemotherapy that extended survival in heavily pretreated breast cancer and in liposarcoma, where almost nothing else had.
Stereotactic body radiotherapy converges multiple beams with sub-millimetre accuracy to deliver tumour-destroying doses in one to five outpatient sessions, doing the job of surgery for inoperable early lung cancer and for metastases in liver, spine and brain. Tumour size and location limit its use, and late toxicity is a concern near the central airways.
- Ablative doses with minimal recovery
- Outpatient
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Do not give if bilirubin above ULN, or AST/ALT above 1.5 x ULN with alkaline phosphatase above 2.5 x ULN (treatment-related deaths).
- Take on an empty stomach (1 hour before or 2 hours after food).
- Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
- 200 mg daily in moderate impairment; avoid in severe.
- Alcohol: avoid (hepatotoxicity). Dexamethasone 20 mg before each dose protects the liver.
- Reduce to 0.9 mg/m² in moderate impairment; avoid in severe.
- Possible QT prolongation. QT prolongation observed on day 8; monitor ECG in patients with heart failure, bradyarrhythmia or QT-prolonging drugs.
- 1.1 mg/m² (mild) or 0.7 mg/m² (moderate).
- 1.1 mg/m² for CrCl 15-49.
- Size and location limits
- Late toxicity near central airways
- Between Gemcitabine, Docetaxel, Pazopanib and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (later lines and oligometastatic), which of the standard options do you recommend and why?Why: Guideline options include: Gemcitabine-docetaxel, pazopanib, trabectedin, eribulin (liposarcoma); pulmonary metastasectomy or stereotactic radiotherapy for limited lung disease; histology-directed agents and trials.
- Am I a candidate for Gemcitabine, Docetaxel, Pazopanib or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.